MX2024002234A - Formulación oftalmológica de ciclosporina estable y proceso de fabricación de esta. - Google Patents

Formulación oftalmológica de ciclosporina estable y proceso de fabricación de esta.

Info

Publication number
MX2024002234A
MX2024002234A MX2024002234A MX2024002234A MX2024002234A MX 2024002234 A MX2024002234 A MX 2024002234A MX 2024002234 A MX2024002234 A MX 2024002234A MX 2024002234 A MX2024002234 A MX 2024002234A MX 2024002234 A MX2024002234 A MX 2024002234A
Authority
MX
Mexico
Prior art keywords
stable
cyclosporine
manufacturing process
nanomicellar
solution
Prior art date
Application number
MX2024002234A
Other languages
English (en)
Spanish (es)
Inventor
Arindam Halder
Ajay Jaysingh Khopade
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MX2024002234A publication Critical patent/MX2024002234A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2024002234A 2021-08-20 2021-10-06 Formulación oftalmológica de ciclosporina estable y proceso de fabricación de esta. MX2024002234A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202121037917 2021-08-20
PCT/IB2021/059176 WO2021224901A2 (en) 2021-08-20 2021-10-06 Stable cyclosporine ophthalmic formulation and manufacturing process thereof

Publications (1)

Publication Number Publication Date
MX2024002234A true MX2024002234A (es) 2024-04-17

Family

ID=78468801

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2024002234A MX2024002234A (es) 2021-08-20 2021-10-06 Formulación oftalmológica de ciclosporina estable y proceso de fabricación de esta.
MX2024002235A MX2024002235A (es) 2021-08-20 2022-08-22 Formulación oftálmica de ciclosporina estable y proceso de fabricación de esta.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024002235A MX2024002235A (es) 2021-08-20 2022-08-22 Formulación oftálmica de ciclosporina estable y proceso de fabricación de esta.

Country Status (8)

Country Link
US (2) US20240342086A1 (https=)
EP (2) EP4387589A4 (https=)
JP (2) JP2024530244A (https=)
CN (2) CN117957011A (https=)
AU (2) AU2021267217A1 (https=)
IL (2) IL310823A (https=)
MX (2) MX2024002234A (https=)
WO (2) WO2021224901A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719350A1 (en) * 2023-05-29 2026-04-08 Sun Pharmaceutical Industries Limited Stable cyclosporine ophthalmic formulation and manufacturing process thereof
WO2025163677A1 (en) * 2024-01-31 2025-08-07 Registrar, Panjab University, Chandigarh Nanomicellar composition for high permeation and extended-release drug delivery system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2836946C (en) * 2011-05-27 2017-08-01 Allergan, Inc. A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
PL2887923T3 (pl) * 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US20200237859A1 (en) * 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
EP3373976B1 (en) * 2015-11-10 2024-01-03 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
US10918694B2 (en) * 2016-02-29 2021-02-16 Sun Pharma Global Fze Topical cyclosporine-containing formulations and uses thereof

Also Published As

Publication number Publication date
EP4387589A2 (en) 2024-06-26
EP4387589A4 (en) 2025-09-03
AU2022330409A1 (en) 2024-02-29
US20240423912A1 (en) 2024-12-26
IL310887A (en) 2024-04-01
EP4387591A1 (en) 2024-06-26
MX2024002235A (es) 2024-06-11
JP2024530245A (ja) 2024-08-16
CN117957011A (zh) 2024-04-30
IL310823A (en) 2024-04-01
WO2021224901A3 (en) 2021-12-30
US20240342086A1 (en) 2024-10-17
JP2024530244A (ja) 2024-08-16
WO2023021492A1 (en) 2023-02-23
CN116528838A (zh) 2023-08-01
AU2021267217A1 (en) 2024-02-29
WO2021224901A2 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2024002234A (es) Formulación oftalmológica de ciclosporina estable y proceso de fabricación de esta.
WO2016183424A8 (en) Light adjustable intraocular lenses using upconverting nanoparticles and near infrared (nir) light
WO2017123383A3 (en) Silk-fibroin hydrogels, methods of forming, and uses thereof
WO2017030917A8 (en) Ocular implant with pressure sensor and delivery system
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
MY201876A (en) Ophthalmic optical lens for vision correction having one or more areas of more positive power
JOP20170147B1 (ar) تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة
MX344394B (es) Procedimiento y aparato para determinar las aberraciones opticas de un ojo.
TW200420275A (en) Devices and methods for improving vision
WO2004055113A8 (en) High refractive index polysiloxane prepolymers
MX374526B (es) Inhibidores de nadph oxidasa 4.
WO2015023884A3 (en) Timed release of substances to treat ocular disorders
MX2024000273A (es) Azetidinil pirimidinas y usos de las mismas.
WO2009044080A3 (fr) Réalisation d'un verre ophtalmique destiné à un porteur
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
DE502005008759D1 (de) In vitro aus knochenmarkstammzellen differenzierteerwendung
MX395496B (es) Uso de co-polímero bi-funcional para aplicaciones oftálmicas y otras aplicaciones tópicas y locales.
DE602006018115D1 (de) Stabilisierte ultraviolettabsorber
WO2005056515A3 (en) Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
PH12022550003A1 (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
WO2013046059A3 (en) Methods and compositions for tamarind-based ocular disease treatment in combination with trehalose
MX2018015091A (es) Composicion para la neutralizacion del veneno de insectos venenosos.
WO2024254489A3 (en) Ophthalmic lenses with light scattering for treating myopia and methods for making the same
WO2023192828A3 (en) Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases